Thursday 30 October 2003
benign vascular tumors
- congenital hemangiomas (RICH and NICH)
- juvenile hemangioma (infantile hemangioma)
- targetoid hemosiderotic hemangioma
- epithelioid hemangioma
- spindle cell hemangioendothelioma
- kaposiform hemangioendothelioma
- epithelioid hemangioendothelioma
- lymphatic malformations
- lymphatic tumors
malignant vascular tumors
- Kaposi sarcoma
- infantile hemangiopericytoma
According to the localization
bone vascular tumors (osseous vascular tumors)
cutaneous vascular tumors
hepatic vascular tumors
muscular vascular tumors
soft tissue vascular tumors
cardiac vascular tumors
Vascular tumors with lobular architecture
lobular capillary hemangioma
some congenital hemangiomas (RICH and NICH)
β-Adrenergic receptor expression in vascular tumors (#22743651#)
Propranolol has recently emerged as an effective therapy for infantile hemangiomas causing regression.
The β-adrenergic receptor (AR) antagonist is thought to cause vasoconstriction by its effect on nitric oxide, block angiogenesis by its effect on vascular endothelial growth factor (VEGF), and induce apoptosis.
The expression of β2-AR (B2-AR) and its phosphorylated form (B2-ARP) have been identified in a case of infantile hemangioma that responded to propranolol treatment.
Although immunohistochemical expression of the receptors does not necessarily indicate that similar pathways of responsiveness to β-blockade are present, it does raises the possibility that β-blockade could potentially affect apoptosis and decrease responsiveness to VEGF.
Vikkula M, Boon LM, Mulliken JB, Olsen BR. Molecular basis of vascular anomalies. Trends Cardiovasc Med. 1998 Oct;8(7):281-92. PMID: #14987552#
β-Adrenergic receptor expression in vascular tumors. Chisholm KM, Chang KW, Truong MT, Kwok S, West RB, Heerema-McKenney AE. Mod Pathol. 2012 Jun 29. PMID: #22743651#